PHESGO 1,200 mg / 600 mg / 30,000 UNT in 15 mL Injection
RxNorm 2382609

Concept Hierarchy & Relationship Mapping

RxNorm Concept Unique Identifier (RxCUI) 2382609 represents a standardized clinical drug concept used for cross-system interoperability. This concept aggregates multiple Atom IDs (AUIs), which are specific naming variations and synonyms used across pharmaceutical databases to ensure accurate medication mapping for: PHESGO 1,200 mg / 600 mg / 30,000 UNT in 15 mL Injection.

The following semantic concepts and normalized strings are associated with this clinical entity:

SBD
15 mL hyaluronidase-zzxf 2000 UNT/ML / pertuzumab-zzxf 80 mg/ML / trastuzumab-zzxf 40 mg/ML Injection [Phesgo]
AUI:12414145
View
PSN
PHESGO 1,200 mg / 600 mg / 30,000 UNT in 15 mL Injection
AUI:12414160
View
SY
Phesgo 1,200 mg / 600 mg / 30,000 UNT per 15 mL Injection
AUI:12414159
View

This clinical crossover tool is designed for healthcare professionals, pharmacists, and data analysts to safely compare substitute products and manage medication interoperability.

SBDPrescribable

Semantic Branded Drug (SBD):
15 mL hyaluronidase-zzxf 2000 UNT/ML / pertuzumab-zzxf 80 mg/ML / trastuzumab-zzxf 40 mg/ML Injection [Phesgo]
(Atom ID: 12414145)

Clinical Status & Identity

Prescribable Status
YES (Active)
Part of the RxNorm Current Prescribable Content subset including all drugs available for prescription in the USA.
Concept Description
15 ML hyaluronidase-zzxf 2000 UNT/ML / pertuzumab-zzxf 80 MG/ML / trastuzumab-zzxf 40 MG/ML Injection [Phesgo]
Official description of the drug concept as defined in the source vocabulary.
Suppress Flag
N
N: Not suppressible | O: Obsolete | Y: Suppressed by editor | E: Unquantified non-prescribable drug.

Interoperability & Coding

Concept ID (RxCUI)
2382609
RxNorm Unique Identifier for the standardized concept.
Atom ID (RXAUI)
12414145
Unique identifier for this specific name variation (Atom).
Term Type (TTY)
SBD
Semantic Branded Drug (Ingredient + Strength + Dose Form + Brand Name)
Source Code
2382609
The "Most useful" identifier asserted by the original source vocabulary.

Source & Registry Data

Source Name
RxNorm Vocabulary (RXNORM)
The official name and abbreviation for the vocabulary source.
Source Version
20AA_260601F
The specific version of the vocabulary provided by the source.
Update Date
June 01, 2026
The date when this RxNorm data was last updated by the NLM.
License Contact
RxNorm Customer Service, , U.S. National Library of Medicine, 8600 Rockville Pike, , Bethesda, MD, United States, 20894, (888) FIND-NLM, , https://support.nlm.nih.gov/support/create-case/, https://www.nlm.nih.gov/research/umls/rxnorm/
Source licensing contact information.

Technical Attributes & Logic

RXN AI
{2382596} 5464
RXCUI of BOSS Active Ingredient preceded by RXCUI of SCDC responsible for value
RXN AI
{2382598} 1298944
RXCUI of BOSS Active Ingredient preceded by RXCUI of SCDC responsible for value
RXN AI
{2382600} 224905
RXCUI of BOSS Active Ingredient preceded by RXCUI of SCDC responsible for value
RXN AM
{2382596} 5464
RXCUI of BOSS Active Moiety preceded by RXCUI of SCDC responsible for value
RXN AM
{2382598} 1298944
RXCUI of BOSS Active Moiety preceded by RXCUI of SCDC responsible for value
RXN AM
{2382600} 224905
RXCUI of BOSS Active Moiety preceded by RXCUI of SCDC responsible for value
RXN AVAILABLE STRENGTH
2000 UNT/ML (expressed as hyaluronidase-zzxf) / 80 MG/ML (expressed as pertuzumab-zzxf) / 40 MG/ML (expressed as trastuzumab-zzxf)
Available drug strengths listed in the order of ingredients from the drug
RXN BOSS FROM
{2382596} AI
Source of BOSS as either from the active ingredient (AI) or the active moiety (AM) preceded by RXCUI of SCDC responsible for value
RXN BOSS FROM
{2382598} AI
Source of BOSS as either from the active ingredient (AI) or the active moiety (AM) preceded by RXCUI of SCDC responsible for value
RXN BOSS FROM
{2382600} AI
Source of BOSS as either from the active ingredient (AI) or the active moiety (AM) preceded by RXCUI of SCDC responsible for value
RXN HUMAN DRUG
US
Drug available for use in Humans
RXN QUANTITY
15 ML
Normal Form quantity factor
PSNPrescribable

Prescribable Name (PSN):
PHESGO 1,200 mg / 600 mg / 30,000 UNT in 15 mL Injection
(Atom ID: 12414160)

Clinical Status & Identity

Prescribable Status
YES (Active)
Part of the RxNorm Current Prescribable Content subset including all drugs available for prescription in the USA.
Concept Description
PHESGO 1,200 MG / 600 MG / 30,000 UNT in 15 ML Injection
Official description of the drug concept as defined in the source vocabulary.
Suppress Flag
N
N: Not suppressible | O: Obsolete | Y: Suppressed by editor | E: Unquantified non-prescribable drug.

Interoperability & Coding

Concept ID (RxCUI)
2382609
RxNorm Unique Identifier for the standardized concept.
Atom ID (RXAUI)
12414160
Unique identifier for this specific name variation (Atom).
Term Type (TTY)
PSN
Prescribable Name (Synonym of another TTY, given for clarity and for display purposes in electronic prescribing applications. Only one PSN per concept.)
Source Code
2382609
The "Most useful" identifier asserted by the original source vocabulary.

Source & Registry Data

Source Name
RxNorm Vocabulary (RXNORM)
The official name and abbreviation for the vocabulary source.
Source Version
20AA_260601F
The specific version of the vocabulary provided by the source.
Update Date
June 01, 2026
The date when this RxNorm data was last updated by the NLM.
License Contact
RxNorm Customer Service, , U.S. National Library of Medicine, 8600 Rockville Pike, , Bethesda, MD, United States, 20894, (888) FIND-NLM, , https://support.nlm.nih.gov/support/create-case/, https://www.nlm.nih.gov/research/umls/rxnorm/
Source licensing contact information.
SYPrescribable

Synonym (SY):
Phesgo 1,200 mg / 600 mg / 30,000 UNT per 15 mL Injection
(Atom ID: 12414159)

Clinical Status & Identity

Prescribable Status
YES (Active)
Part of the RxNorm Current Prescribable Content subset including all drugs available for prescription in the USA.
Concept Description
Phesgo 1,200 MG / 600 MG / 30,000 UNT per 15 ML Injection
Official description of the drug concept as defined in the source vocabulary.
Suppress Flag
N
N: Not suppressible | O: Obsolete | Y: Suppressed by editor | E: Unquantified non-prescribable drug.

Interoperability & Coding

Concept ID (RxCUI)
2382609
RxNorm Unique Identifier for the standardized concept.
Atom ID (RXAUI)
12414159
Unique identifier for this specific name variation (Atom).
Term Type (TTY)
SY
Synonym (Synonym of another TTY, given for clarity.)
Source Code
2382609
The "Most useful" identifier asserted by the original source vocabulary.

Source & Registry Data

Source Name
RxNorm Vocabulary (RXNORM)
The official name and abbreviation for the vocabulary source.
Source Version
20AA_260601F
The specific version of the vocabulary provided by the source.
Update Date
June 01, 2026
The date when this RxNorm data was last updated by the NLM.
License Contact
RxNorm Customer Service, , U.S. National Library of Medicine, 8600 Rockville Pike, , Bethesda, MD, United States, 20894, (888) FIND-NLM, , https://support.nlm.nih.gov/support/create-case/, https://www.nlm.nih.gov/research/umls/rxnorm/
Source licensing contact information.

Patient Education

Pertuzumab, Trastuzumab, and Hyaluronidase-zzxf Injection


The combination of pertuzumab, trastuzumab, and hyaluronidase-zzxf is used in combination with chemotherapy to treat certain types of early breast cancer that has spread to nearby tissues. It is also used to treat a certain type of early breast cancer to decrease the chance that a certain type of breast cancer will return. The combination of pertuzumab, trastuzumab, and hyaluronidase-zzxf is also used with docetaxel (Taxotere) to treat certain types of breast cancer that has spread to other parts of the body. Pertuzumab and trastuzumab are in a class of medications called monoclonal antibodies. They work by stopping the growth of cancer cells. Hyaluronidase is an endoglycosidase. It helps to keep pertuzumab and trastuzumab in the body longer so that these medications will have a greater effect.
[Learn More]


* Please review the disclaimer below.